EUVIMEDEUVIMED entdecken
Crossref

Dual-Responsive Nanomedicine Activates Programmed Antitumor Immunity through Targeting Lymphatic System

Hong Xiao iD, Xiaoxia Li, Simin Liang, Shuguang Yang, Shisong Han iD, Jinsheng Huang iD, Xintao Shuai iD, Jie Ren

ACS Nano · 30.04.2024 · 18 (17) · 11070-11083

DOI: 10.1021/acsnano.3c11464 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Nano, online erschienen am 19.04.2024. Verfasst von Hong Xiao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Ultrasonic, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China. Hauptthemen laut MEDLINE: Nanomedicine. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Sun Yat-sen University, Key Technologies Research and Development Program of Guangzhou Municipality, Basic and Applied Basic Research Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Effective antitumor immunotherapy depends on evoking a cascade of cancer-immune cycles with lymph nodes (LNs) as the initial sites for activating antitumor immunity, making drug administration through the lymphatic system highly attractive. Here, we describe a nanomedicine with dual responsiveness to pH and enzyme for a programmed activation of antitumor immune through the lymphatic system. The proposed nanomedicine can release the STING agonist diABZI-C2-NH2 in the LNs' acidic environment to activate dendritic cells (DCs) and T cells. Then, the remaining nanomedicine hitchhikes on the activated T cells (PD-1+ T cells) through binding to PD-1, resulting in an effective delivery into tumor tissues owing to the tumor-homing capacity of PD-1+ T cells. The enzyme matrix metalloproteinase-2 (MMP-2) being enriched in tumor tissue triggers the release of PD-1 antibody (aPD-1) which exerts immune checkpoint blockade (ICB) therapy. Eventually, the nanomedicine delivers a DNA methylation inhibitor GSK-3484862 (GSK) into tumor cells, and then the latter combines with granzyme B (GZMB) to trigger tumor cell pyroptosis. Consequently, the pyroptotic tumor cells induce robust immunogenic cell death (ICD) enhancing the DCs maturation and initiating the cascading antitumor immune response. Study on a 4T1 breast tumor mouse model demonstrates the prominent antitumor therapeutic outcome of this nanomedicine through creating a positive feedback loop of cancer-immunity cycles including immune activation in LNs, T cell-mediated drug delivery, ICB therapy, and tumor cell pyroptosis-featured ICD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanomedicineAnimalsMiceHumansImmunotherapyFemaleLymph NodesDendritic CellsProgrammed Cell Death 1 ReceptorAntineoplastic AgentsCell Line, Tumor

Stichwörter der Autor:innen

antitumor immunotherapydual-responsive nanomedicinelymphoid targetingprogrammed immune activationsequential drug release

Substanzen

Programmed Cell Death 1 ReceptorAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Medical Ultrasonic, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
  • Nanomedicine Research Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
  • PCFM Lab of Ministry of Education, School of Materials Science and Engineering, Sun Yat-sen University, Guangzhou 510275, China.

ORCID-Profile: Hong Xiao, Shisong Han, Jinsheng Huang, Xintao Shuai

Förderung

  • Sun Yat-sen University
  • Key Technologies Research and Development Program of Guangzhou Municipality
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • National Natural Science Foundation of China

Zitieren

APA

Xiao, H., Li, X., Liang, S., Yang, S., Han, S., Huang, J., Shuai, X., & Ren, J. (2024). Dual-Responsive Nanomedicine Activates Programmed Antitumor Immunity through Targeting Lymphatic System. ACS Nano, 18(17), 11070-11083. https://doi.org/10.1021/acsnano.3c11464

Vancouver

Xiao H, Li X, Liang S, Yang S, Han S, Huang J, et al. Dual-Responsive Nanomedicine Activates Programmed Antitumor Immunity through Targeting Lymphatic System. ACS Nano. 2024;18(17):11070-11083. doi:10.1021/acsnano.3c11464

BibTeX
@article{Xiao2024,
  author = {Xiao, Hong and Li, Xiaoxia and Liang, Simin and Yang, Shuguang and Han, Shisong and Huang, Jinsheng and Shuai, Xintao and Ren, Jie},
  title = {Dual-Responsive Nanomedicine Activates Programmed Antitumor Immunity through Targeting Lymphatic System},
  journal = {ACS Nano},
  year = {2024},
  volume = {18},
  number = {17},
  pages = {11070--11083},
  doi = {10.1021/acsnano.3c11464}
}
Kostenlos starten →